[go: up one dir, main page]

CL2018002930A1 - (+)-azasetron para uso en el tratamiento de desórdenes de oído. - Google Patents

(+)-azasetron para uso en el tratamiento de desórdenes de oído.

Info

Publication number
CL2018002930A1
CL2018002930A1 CL2018002930A CL2018002930A CL2018002930A1 CL 2018002930 A1 CL2018002930 A1 CL 2018002930A1 CL 2018002930 A CL2018002930 A CL 2018002930A CL 2018002930 A CL2018002930 A CL 2018002930A CL 2018002930 A1 CL2018002930 A1 CL 2018002930A1
Authority
CL
Chile
Prior art keywords
azasetron
treatment
ear disorders
disorders
ear
Prior art date
Application number
CL2018002930A
Other languages
English (en)
Inventor
Jonas Dyhrfjeld-Johnsen
Original Assignee
Sensorion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sensorion filed Critical Sensorion
Publication of CL2018002930A1 publication Critical patent/CL2018002930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A (+)-AZASETRÓN, O UNA SAL Y/O SOLVATO FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, PARA TRATAR TRASTORNOS DEL OÍDO.
CL2018002930A 2016-04-14 2018-10-12 (+)-azasetron para uso en el tratamiento de desórdenes de oído. CL2018002930A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662322690P 2016-04-14 2016-04-14
EP16180192 2016-07-19

Publications (1)

Publication Number Publication Date
CL2018002930A1 true CL2018002930A1 (es) 2019-02-15

Family

ID=65588799

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018002930A CL2018002930A1 (es) 2016-04-14 2018-10-12 (+)-azasetron para uso en el tratamiento de desórdenes de oído.

Country Status (18)

Country Link
US (2) US11612605B2 (es)
EP (1) EP4335508A3 (es)
JP (1) JP7158723B2 (es)
CN (1) CN109310698B (es)
AU (1) AU2023202897B2 (es)
CL (1) CL2018002930A1 (es)
DK (1) DK3442537T3 (es)
ES (1) ES2975016T3 (es)
FI (1) FI3442537T3 (es)
HR (1) HRP20240453T1 (es)
HU (1) HUE066000T2 (es)
IL (1) IL262305B (es)
MX (1) MX384045B (es)
NZ (1) NZ747201A (es)
PL (1) PL3442537T3 (es)
RS (1) RS65379B1 (es)
SI (1) SI3442537T1 (es)
ZA (1) ZA201806894B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297628B1 (en) * 2015-05-18 2021-06-09 Sensorion Azasetron for use in the treatment of hearing loss

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US5360800A (en) 1987-09-03 1994-11-01 Glaxo Group Limited Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
CA1304082C (en) 1987-10-22 1992-06-23 Tetsuya Tahara Benzoxazine compounds and pharmaceutical use thereof
GB9423511D0 (en) 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB0009914D0 (en) 2000-04-20 2000-06-07 Metris Therapeutics Limited Device
GB0104554D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New uses
US20030044356A1 (en) 2001-04-20 2003-03-06 Jin Auh Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
US20030229333A1 (en) * 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
GB0213869D0 (en) 2002-06-17 2002-07-31 Arakis Ltd The treatment of pain
KR20050094843A (ko) 2003-01-13 2005-09-28 다이노젠 파마세우티컬스, 인코포레이티드 욕지기, 구토, 구역질 또는 이들의 조합을 치료하는 방법
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US20040204466A1 (en) 2003-04-14 2004-10-14 Orchid Chemicals And Pharmaceuticals Ltd. Treatment of bronchial asthma using 5-HT3 receptor antagonists
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
JP5491502B2 (ja) 2008-07-14 2014-05-14 オトノミ―，インク． 制御放出アポトーシス調節化合物および耳の障害の処置のための方法
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
KR101779991B1 (ko) 2009-05-20 2017-09-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 병소성 전정 질환을 치료하기 위한 세로토닌 5-ｈｔ3 수용체 길항제의 용도
CN101786963B (zh) 2010-03-03 2013-05-08 山东众诚药业股份有限公司 阿扎司琼中间体的合成方法
US10188695B2 (en) 2012-02-23 2019-01-29 Sensorion Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
ES2785303T3 (es) 2012-07-16 2020-10-06 Univ Cornell Nicotinamida ribósido para tratar la pérdida auditiva
EP3027172B1 (en) * 2013-07-31 2020-09-16 Bluepharma - Industria Farmacêutica, S.A. Oral dispersible films
CN104557906A (zh) 2015-01-21 2015-04-29 扬子江药业集团四川海蓉药业有限公司 一种盐酸阿扎司琼的制备方法
EP3297628B1 (en) 2015-05-18 2021-06-09 Sensorion Azasetron for use in the treatment of hearing loss

Also Published As

Publication number Publication date
RS65379B1 (sr) 2024-04-30
CN109310698A (zh) 2019-02-05
EP4335508A2 (en) 2024-03-13
MX2018012587A (es) 2019-03-07
ES2975016T3 (es) 2024-07-02
CN109310698B (zh) 2021-12-24
AU2023202897B2 (en) 2025-01-30
FI3442537T3 (fi) 2024-04-04
DK3442537T3 (da) 2024-03-25
NZ747201A (en) 2023-02-24
JP2019513780A (ja) 2019-05-30
IL262305B (en) 2022-03-01
ZA201806894B (en) 2023-03-29
HUE066000T2 (hu) 2024-06-28
JP7158723B2 (ja) 2022-10-24
SI3442537T1 (sl) 2024-05-31
AU2023202897A1 (en) 2023-05-25
HRP20240453T1 (hr) 2024-06-21
EP4335508A3 (en) 2024-07-10
US20230226071A1 (en) 2023-07-20
PL3442537T3 (pl) 2024-07-15
IL262305A (en) 2018-11-29
MX384045B (es) 2025-03-14
US20190083503A1 (en) 2019-03-21
US11612605B2 (en) 2023-03-28

Similar Documents

Publication Publication Date Title
MX2019009443A (es) Metodos para tratar la influenza.
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
DOP2017000111A (es) Inhibidor de cinasa aurora a
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX378273B (es) Compuestos activos hacia bromodominios.
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
CL2017000050A1 (es) Terapia de combinación para el cáncer
AR103680A1 (es) Inhibidores selectivos de bace1
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2019014024A (es) Tratamiento de los trastornos depresivos.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
CL2019002325A1 (es) Combinaciones farmacéuticas para tratar cáncer.
MX392383B (es) Metodos para tratar afecciones oculares.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
UA116499C2 (uk) (r)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
MX2018004632A (es) Metodos y composiciones para el tratamiento de una lesion cerebral traumatica.
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
SG10201903630UA (en) Iminosugars useful for the treatment of viral diseases